Two series of 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives incorporating an additional site for
acid salt formation were synthesized and evaluated as inhibitors of human blood platelet
cAMP phosphodiesterase (PDE) and
ADP-induced platelet aggregation. The objective of this study was to identify compounds that blended potent
biological activity with a satisfactory level of aqueous solubility. From a series of 7-aminoimidazo[4,5-b]quinolin-2-ones,
biological and physical properties were optimally combined in the 1-piperidinyl derivative 11c. However, this compound offered no significant advantage over earlier studied compounds as an
antithrombotic agent in an animal model of small vessel
thrombosis. A series of 7-alkoxy alkanoic piperazinamide derivatives, in which the additional basic
nitrogen atom was remote from the heterocyclic nucleus and accommodated in a secondary binding region of the cAMP PDE
enzyme, demonstrated greater intrinsic cAMP PDE inhibitory activity. Structural modifications of this series focused on variation of the
piperazine substituent and side-chain length. The lipophilicity of the N-substituent influenced
biological potency and aqueous solubility, with substituents of seven
carbon atoms or less generally providing acceptable solubility properties. The N-(cyclohexylmethyl)piperazinamide 21h was identified from this series of compounds as a potent inhibitor of platelet cAMP PDE, IC50 = 0.4 nM, and
ADP-induced platelet aggregation, IC50 = 0.51 microM after a 3-min exposure and 0.1 microM after a 15-min exposure of platelet-rich plasma to the
drug. Evaluation of 21h and representative analogues in vivo using a rabbit model of small vessel
thrombosis revealed significantly greater antithrombotic efficacy compared to that of previously studied compounds with similar intrinsic
biological activity measured in vitro but inferior aqueous solubility.